【disadvantages of generation skipping trust】Halozyme Therapeutics, Inc. Just Recorded A 24% EPS Beat: Here's What Analysts Are Forecasting Next
As you might know,disadvantages of generation skipping trust
Halozyme Therapeutics, Inc.
(
NASDAQ:HALO
) just kicked off its latest third-quarter results with some very strong numbers. It was a solid earnings report, with revenues and statutory earnings per share (EPS) both coming in strong. Revenues were 10% higher than the analysts had forecast, at US$65m, while EPS were US$0.25 beating analyst models by 24%. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
See our latest analysis for Halozyme Therapeutics
earnings-and-revenue-growth
Taking into account the latest results, the most recent consensus for Halozyme Therapeutics from ten analysts is for revenues of US$381.4m in 2021 which, if met, would be a huge 91% increase on its sales over the past 12 months. Statutory earnings per share are predicted to soar 846% to US$1.48. In the lead-up to this report, the analysts had been modelling revenues of US$361.3m and earnings per share (EPS) of US$1.41 in 2021. It looks like there's been a modest increase in sentiment following the latest results, withthe analysts becoming a bit more optimistic in their predictions for both revenues and earnings.
With these upgrades, we're not surprised to see that the analysts have lifted their price target 5.6% to US$34.55per share. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Halozyme Therapeutics, with the most bullish analyst valuing it at US$45.00 and the most bearish at US$15.00 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The analysts are definitely expecting Halozyme Therapeutics' growth to accelerate, with the forecast 91% growth ranking favourably alongside historical growth of 7.0% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 21% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Halozyme Therapeutics to grow faster than the wider industry.
Story continues
The Bottom Line
The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Halozyme Therapeutics' earnings potential next year. Happily, they also upgraded their revenue estimates, and are forecasting revenues to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Halozyme Therapeutics going out to 2024, and you can
see them free on our platform here.
You should always think about risks though. Case in point, we've spotted
3 warning signs for Halozyme Therapeutics
you should be aware of, and 2 of them are a bit concerning.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content?
Get in touch
with us directly.
Alternatively, email
.
View comments
-
Omaha Public Facilities Corporation, NE -- Moody's assigns Aa2 to Omaha, NE's lease bonds; outlook stableIs There Now An Opportunity In Sotherly Hotels Inc. (NASDAQ:SOHO)?Expanse Integrates with ServiceNowMachinery Companies' Earnings Due on Nov 5: PH, MIDD & FLSZuora's (ZUO) Loss Narrows in Q1, Revenues Increase Y/YIMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Beyond Meat, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmPatrick Downey Is The President of Orezone Gold Corporation (CVE:ORE) And They Just Spent US$108k On SharesWhat Is MDU Resources Group's (NYSE:MDU) P/E Ratio After Its Share Price Tanked?Microsoft (MSFT) Is a Bargain Stock You Can Buy TodayBarry Manilow and Darryl Payne Settle Copyright Dispute
下一篇:Will AudioEye Continue to Surge Higher?
- ·Were Hedge Funds Right About Advanced Micro Devices, Inc. (AMD)?
- ·Cargotec completes the ownership change of joint venture in China
- ·Portugal says unacceptable to block EU recovery funds
- ·Is AquaBounty Technologies (NASDAQ:AQB) Using Too Much Debt?
- ·CME Group (CME) Reports Soft May Volumes, Shares Decline
- ·Masco Banks on Repair & Remodeling Business Amid High Costs
- ·3 Reasons Growth Investors Will Love Charles River (CRL)
- ·SHAREHOLDER ALERT: CLAIMSFILER REMINDS FSCT, WFC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
- ·ESSA Bank & Trust Forms Relationship with Ameriprise Financial to Expand Financial Planning and Investment Services
- ·Is the Options Market Predicting a Spike in Seagate (STX) Stock?
- ·Are You Looking for a Top Momentum Pick? Why Vapotherm (VAPO) is a Great Choice
- ·Egypt tries to protect tourism after coronavirus outbreak on cruise ship
- ·People are getting this unexpected stimulus check. Should you keep it?
- ·Preview: Signet Jewelers's Earnings
- ·National CineMedia (NCMI) Jumps: Stock Rises 10.6%
- ·Pence will meet cruise industry officials Saturday on coronavirus
- ·Where Do Hedge Funds Stand On Pacific Mercantile Bancorp (PMBC)?
- ·Pennsylvania's Democratic governor calls Trump remarks 'partisan attack'
- ·Canada energy firms fret as Ottawa labors over promised aid package
- ·After Facebook deal, Reliance Jio rakes in $747 million from PE giant Silver Lake
- ·Our Take On Avery Dennison's (NYSE:AVY) CEO Salary
- ·Barr Finds No Election Fraud as DOJ Pursues ‘Bribery for Pardons’ Scheme
- ·The Best Places in Every State To Live on a Fixed Income
- ·Natural Gas Price Fundamental Weekly Forecast – Heating Season Begins with Hedge Funds Holding Long Positions
- ·240,000 U.S. Virus Deaths Don't Have to Happen
- ·EXCLUSIVE: Frédéric Arnault Gears Up for CEO Role at Tag Heuer
- ·Do Hedge Funds Love Brooge Energy Limited (BROG)?
- ·Avenue Therapeutics Announces Publications in Peer-Reviewed Journals
- ·Lockheed Martin (LMT) Wins $1B Deal for Super Hercules Fleet
- ·How Much Is Live Nation Entertainment, Inc. (NYSE:LYV) CEO Getting Paid?
- ·Peru's president accuses AG of damaging big corruption probe
- ·Paycom Software, Inc. to Host Earnings Call
- ·US$4.75 - That's What Analysts Think Century Aluminum Company (NASDAQ:CENX) Is Worth After These Results
- ·Exclusive: StanChart says CEO Winters will stay to execute current strategy
- ·How Are PlayStation 5, Xbox Poised Before Launch?
- ·Waiting for passengers, American puts Boeing Max in the air